Daxor (DXR) Q4 2024 earnings summary

Executive summary

• Net assets increased to $36.8M ($7.25/share) at year-end 2024, up from $34.1M ($7.08/share) in 2023, driven by operating division appreciation.

• Achieved cash flow break-even in Q1 2025 (excluding non-cash items), with revenue up 116.5% year-over-year in 2024 and over 100% growth in early 2025.

• Expanded clinical adoption, partnerships, and product utilization across multiple medical disciplines and care settings.

• Entered agreements to acquire key supplier IP, internalize manufacturing, and add new diagnostic products, expected to be accretive to earnings.

Financial highlights

• Net dividend income of $104K and net realized gains on investments of $1.36M in 2024.

• Net decrease in unrealized appreciation on investments of $1.15M due to sales of previously appreciated positions.

• Non-cash stock-based compensation expense of $1.25M included in 2024 results.

• $1.61M invested in operating division for R&D, sales, and production ramp-up for 2025 product launch.

• Revenue in the first two months of 2025 more than doubled compared to the same period in 2024.

Outlook and guidance

• Anticipates significant growth from next-generation analyzer launch, with FDA 510(k) submission imminent and CLIA waiver to follow.

• Expects new product launches and internalized manufacturing to increase margins and cash flow.

• Management aims to transition SEC reporting status to reflect operating company focus by end of 2025.